Child Resistant Closures
Global Child Resistant Closures Market to Reach $2 Billion by 2027
Amid the COVID-19 crisis, the global market for Child Resistant Closures estimated at US$1.5 Billion in the year 2020, is projected to reach a revised size of US$2 Billion by 2027, growing at a CAGR of 3.9% over the analysis period 2020-2027. Push and Turn, one of the segments analyzed in the report, is projected to record a 4.1% CAGR and reach US$1.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Squeeze and Turn segment is readjusted to a revised 3.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $404.9 Million, While China is Forecast to Grow at 7.1% CAGR
The Child Resistant Closures market in the U.S. is estimated at US$404.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$419.6 Million by the year 2027 trailing a CAGR of 7.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.2% and 3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2% CAGR.
Other Closure Types Segment to Record 2.7% CAGR
In the global Other Closure Types segment, USA, Canada, Japan, China and Europe will drive the 2.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$111.4 Million in the year 2020 will reach a projected size of US$130.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$278 Million by the year 2027, while Latin America will expand at a 3.5% CAGR through the analysis period.
Select Competitors (Total 42 Featured) -
- Amcor Ltd.
- AptarGroup, Inc.
- Bericap GmbH Co. & KG
- Berry Global, Inc.
- Blackhawk Molding Co, Inc.
- C.L. Smith Company
- Closure Systems International, Inc.
- Georg MENSHEN GmbH & Co. KG
- Global Closure Systems
- Guala Closures Group
- Mold-Rite Plastics
- O.Berk Company LLC
- Parekhplast India Ltd.
- Plastic Closures Ltd.
- Silgan Plastics LLC
- Tecnocap SpA
- United Caps Luxembourg S.A.
- Weener Plastik GmbH
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 2: World Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 3: World 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
- TABLE 4: World Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 5: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 6: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 7: World Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 8: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 9: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 10: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 11: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 12: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 13: World Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 14: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 15: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 16: World Current & Future Analysis for Diagnostic Centers Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 17: World Historic Review for Diagnostic Centers Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 18: World 15-Year Perspective for Diagnostic Centers Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 19: World Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 20: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 21: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 22: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 23: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 24: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- III. MARKET ANALYSIS
- UNITED STATES
- TABLE 25: USA Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 26: USA Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 27: USA 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 28: USA Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 29: USA Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 30: USA 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- CANADA
- TABLE 31: Canada Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 32: Canada Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 33: Canada 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 34: Canada Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 35: Canada Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 36: Canada 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- JAPAN
- TABLE 37: Japan Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 38: Japan Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 39: Japan 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 40: Japan Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 41: Japan Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 42: Japan 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- CHINA
- TABLE 43: China Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 44: China Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 45: China 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 46: China Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 47: China Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 48: China 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- EUROPE
- TABLE 49: Europe Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 50: Europe Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 51: Europe 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
- TABLE 52: Europe Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 53: Europe Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 54: Europe 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 55: Europe Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 56: Europe Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 57: Europe 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- FRANCE
- TABLE 58: France Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 59: France Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 60: France 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 61: France Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 62: France Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 63: France 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- GERMANY
- TABLE 64: Germany Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 65: Germany Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 66: Germany 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 67: Germany Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 68: Germany Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 69: Germany 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- ITALY
- TABLE 70: Italy Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 71: Italy Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 72: Italy 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 73: Italy Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 74: Italy Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 75: Italy 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- UNITED KINGDOM
- TABLE 76: UK Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 77: UK Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 78: UK 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 79: UK Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 80: UK Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 81: UK 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- SPAIN
- TABLE 82: Spain Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 83: Spain Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 84: Spain 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 85: Spain Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 86: Spain Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 87: Spain 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- RUSSIA
- TABLE 88: Russia Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 89: Russia Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 90: Russia 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 91: Russia Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 92: Russia Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 93: Russia 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- REST OF EUROPE
- TABLE 94: Rest of Europe Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 95: Rest of Europe Historic Review for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Diagnostics and Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 96: Rest of Europe 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by Product Type - Percentage Breakdown of Value Sales for Diagnostics and Therapeutics for the Years 2012, 2020 & 2027
- TABLE 97: Rest of Europe Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 98: Rest of Europe Historic Review for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 99: Rest of Europe 15-Year Perspective for Chlamydia Infection Diagnostics and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies and Other End-Uses for the Years 2012, 2020 & 2027
- ASIA-PACIFIC
- TABLE 100: Asia-Pacific Current & Future Analysis for Chlamydia Infection Diagnostics and Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR